niacinamide has been researched along with Endometriosis in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Endometriosis: A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is a strong multikinase inhibitor targeting 2 different pathways of endometriosis pathogenesis: RAF kinase and vascular endothelial growth factor receptor (VEGFR)." | 7.81 | Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. ( Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P, 2015) |
| "Patients receiving surgical treatment of endometriosis (n = 4) and control patients without endometriosis (n = 2) undergoing surgery for benign gynecologic diseases." | 5.38 | Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. ( Bussolati, B; Cassoni, P; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A, 2012) |
| "Sorafenib is a strong multikinase inhibitor targeting 2 different pathways of endometriosis pathogenesis: RAF kinase and vascular endothelial growth factor receptor (VEGFR)." | 3.81 | Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. ( Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P, 2015) |
| "Endometriosis is characterized by disabling symptoms that afflict young women with severe physical discomfort, difficulty in relationship life, and infertility; however, the currently available therapeutic strategies are unsatisfactory." | 1.48 | Novel dietary supplement association reduces symptoms in endometriosis patients. ( Baldi, A; Signorile, PG; Viceconte, R, 2018) |
| "Patients receiving surgical treatment of endometriosis (n = 4) and control patients without endometriosis (n = 2) undergoing surgery for benign gynecologic diseases." | 1.38 | Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. ( Bussolati, B; Cassoni, P; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Signorile, PG | 1 |
| Viceconte, R | 1 |
| Baldi, A | 1 |
| Pittatore, G | 2 |
| Moggio, A | 2 |
| Benedetto, C | 1 |
| Bussolati, B | 2 |
| Revelli, A | 2 |
| Yildiz, C | 1 |
| Kacan, T | 1 |
| Akkar, OB | 2 |
| Karakus, S | 1 |
| Kacan, SB | 1 |
| Ozer, H | 2 |
| Cetin, A | 1 |
| Leconte, M | 1 |
| Santulli, P | 1 |
| Chouzenoux, S | 1 |
| Marcellin, L | 1 |
| Cerles, O | 1 |
| Chapron, C | 1 |
| Dousset, B | 1 |
| Batteux, F | 1 |
| Boztosun, A | 1 |
| Açmaz, G | 1 |
| Atilgan, R | 1 |
| Kosar, MI | 1 |
| Cassoni, P | 1 |
| Marchino, GL | 1 |
| Morotti, M | 1 |
| Ferrero, S | 1 |
1 review available for niacinamide and Endometriosis
| Article | Year |
|---|---|
Endometrial adult/progenitor stem cells: pathogenetic theory and new antiangiogenic approach for endometriosis therapy.
Topics: Adult; Adult Stem Cells; Angiogenesis Inhibitors; Animals; Endometriosis; Endometrium; Female; Human | 2014 |
6 other studies available for niacinamide and Endometriosis
| Article | Year |
|---|---|
Novel dietary supplement association reduces symptoms in endometriosis patients.
Topics: Adult; Curcumin; Dietary Supplements; Endometriosis; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Fem | 2018 |
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease | 2015 |
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models | 2015 |
The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Models, Anima | 2013 |
Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis.
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Cell Movement; Cell Proliferation; Cells, Culture | 2012 |
Antiangiogenic drugs in the treatment of endometriosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Disease Models, Animal; Endometriosis; Female; Niacinami | 2013 |